75 results about "Human plasma" patented technology

Provided herein are compositions comprising allogeneic human plasma and platelet derived product, and methods for making the compositions and using the compositions as a therapeutic for example, in orthopedic indications.

The invention relates to the field of blood products, in particular to a preparation method of human activated C1 esterase. The preparation method comprises the following steps: carrying out contact adsorption on cryoprecipitate-removed human plasma and anion exchange resin, washing and eluting to obtain an eluent containing C1 proesterase, carrying out membrane filtration, and carrying out ultrafiltration desalination treatment; adding an anionic substance into the eluent, incubating in vitro to effectively activate the C1 esterase, and filtering by a membrane to obtain a feed liquid containing the activated C1 esterase; and carrying out purification treatment on the feed liquid to obtain the human activated C1 esterase, and carrying out cryopreservation. According to the method, an anion substance is introduced into an eluent system obtained through anion exchange, mild and effective activation of the C1 proesterase is achieved under the condition of not depending on foreign proteolytic enzyme, the risk of non-specific hydrolysis and self-cutting inactivation is remarkably reduced, good synergy is formed with a follow-up purification process, and the method is suitable for industrial production. The human activated C1 esterase product with relatively high activity and good stability is obtained.

FIELD: pharmacology.SUBSTANCE invention can be used to determine the concentration of an anti-tuberculosis drug in blood serum. The method for determining the concentration of bedaquiline in the blood serum in patients with tuberculosis or mycobacteriosis is that whole blood samples are centrifuged at 3000 rpm for 20 minutes, then the blood plasma is collected in sterile 1.5 mL Eppendorf tubes, then 900 mcL of acetonitrile are added to 300 mcL of plasma and centrifuged at 13500g for 15 minutes, then 1 mL of the supernatant is transferred to a chromatographic vial and make the assay by UHPLC MS / MS using an Athena UHPLC C18, 1.8 mcM, 120A, 2.1×100 mm chromatography column, when using an aqueous solution containing 5 g / L of ammonium acetate, 25 ml / L of concentrated acetic acid, 2 ml / L trifluoroacetic acid as mobile phase A and 100% acetonitrile as mobile phase B, the concentration of bedaquiline is determined using a pre-plotted calibration curve.EFFECT: determination of bedaquiline in human blood plasma in a time not exceeding 6 minutes.1 cl, 9 dwg, 6 tbl

The invention relates to the technical field of pollution treatment equipment, and discloses a syphilis patient plasma pollutant treatment device which comprises a bottom plate, and a mounting frame is fixedly connected to the middle of the top end of the bottom plate; the electromagnetic separation mechanism is arranged in the middle of the top end of the mounting frame and used for separating plasma pollutants of the syphilis patient in an electromagnetic treatment mode; and the regeneration and recovery mechanism is arranged on one side of the top of the mounting frame. By adding and arranging the regeneration and recovery mechanism, when plasma pollutants of syphilis patients are treated, the mechanism can thoroughly recover magnetic nanoparticles in a quartz separation column through flexible switching of conveying of eluent and regeneration liquid through a first three-way solenoid valve, precise liquid supply through combination of a first conveying pump and auxiliary elution through cooperation of an ultrasonic oscillator; and the compound and the particles can be separated through centrifugal treatment of the centrifugal cylinder, the regeneration liquid can enable the particles to be renatured and restore activity, and reutilization is achieved.

The invention provides a method for detecting the drug concentration of bevacizumab. The method comprises the following steps: taking a solution containing infliximab as an internal standard working solution, and determining the drug concentration of the bevacizumab in a sample to be detected by adopting liquid chromatography-tandem mass spectrometry. In drug monitoring for clinical detection of the bevacizumab concentration in human plasma, infliximab is adopted as an internal standard, the detection requirement can be effectively met, and the detection cost is reduced. The infliximab serves as an internal standard, methodological requirements of the established method can be met, and accuracy and reliability of detection results are ensured. In addition, by optimizing the sample pretreatment process, the operation steps are simplified, the detection time is shortened, manual operation errors are reduced, and the detection accuracy and efficiency are further improved.

The present invention provides a method of fractionating human plasma, in some embodiments, using the Cohn fractionation procedure. The improvement comprises the use of physiologically active concentrated plasma as the starting material for the fractionation procedure.

The invention relates to the technical field of drug monitoring, and mainly relates to a method for detecting multiple antitumor drugs and metabolites in human plasma through liquid chromatography-tandem mass spectrometry and application of the method. The medicine to be detected is prepared from cevaltinib, loratinib, vomitinib, amitinib, sovantinib, anlotinib, glutamitinib, emtricitinib, N-demethylated vomitinib and N-demethylated emtricitinib; s2, preparing a calibration product and a quality control product, and preparing a working curve concentration table; s3, carrying out pretreatment on the calibration product and the quality control product obtained in the step S2; s4, carrying out liquid chromatography-tandem mass spectrometry detection on the pretreated liquid; and S5, performing methodological verification on the detection method. The detection method has the advantages of high sensitivity, good detection result accuracy, simple and rapid detection process, short analysis time and the like, and is suitable for detection of large-flux samples.

A process for synthesizing and separating secretory IgA from a mixture of IgA monomer and IgA dimer is provided The process includes covalently binding affinity tagged or epitope tagged recombinant secretory component to the IgA dimer in the mixture and then binding the affinity tagged or an epitope tagged secretory IgA to immobilized moieties on the solid phase support resin to which the affinity tag or epitope tag binds and then eluting the affinity tagged or an epitope tagged secretory IgA with release buffer. A process for synthesizing and separating secretory IgM from a mixture of IgM and other plasma proteins is provided. A process is provided for inhibiting or preventing symptoms of necrotizing enterocolitis in a subject that includes the oral administration to the subject of a human polyclonal secretory IgA formed by the conjugation of human recombinant secretory component and pooled human plasma derived dimeric and polymeric.

The invention relates to a method for extracting human alpha1-antitrypsin from plasma by a full chromatography method. According to the method, specifically, human plasma or a flow-through liquid obtained after Pg, Fg, IgG and Alb are sequentially extracted from the human plasma is used as a raw material, chromatography preparation is conducted through a two-step chromatography method of CM FF cation exchange chromatography and DEAE FF ion exchange chromatography, according to the method, the yield of human alpha1-antitrypsin is larger than 400 g on the basis of 1000 L of plasma, and the relative purity of a product is larger than 99%.

The invention relates to a method for measuring the concentration of cefadroxil in K2EDTA human plasma through LC-MS / MS. The method comprises the following steps: preparing a standard curve solution containing cefadroxil d4 by taking K2EDTA human plasma as a matrix, preparing a test solution containing cefadroxil, and precipitating the solution by using acetonitrile; determining the concentration of the test solution containing cefadroxil after precipitation by using an internal standard method; a liquid chromatography tandem mass spectrometer is used for determination, a mobile phase of liquid chromatography is composed of a mobile phase A and a mobile phase B, the mobile phase A is an acetic acid aqueous solution, and the mobile phase B is acetonitrile; the elution procedure of the liquid chromatography is isocratic elution, the volume content of acetonitrile in a mobile phase is 10-30%, and the flow velocity of the mobile phase is 0.4-0.8 mL / min. By optimizing chromatographic conditions and mass spectrum parameters, an efficient and accurate cefadroxil concentration detection method is provided, and the accuracy and reliability of data are ensured.

The present application relates to a kind of HPLC-MS / MS detection method of detecting in human plasma, desloratadine and 3-hydroxydesloratadine in human plasma, it includes the following steps: (1) human plasma sample pretreatment;(2) liquid chromatography-mass spectrometry detection, using mobile phase A and mobile phase B as mixed mobile phase is carried out gradient elution, wherein: mobile phase A is methanol-acetonitrile mixed solution, in mixed solution methanol and acetonitrile volume ratio is 4-6:6-4;Mobile phase B is 2-20mM ammonium formate aqueous solution;(3) the determination of the concentration of human plasma in lopatadine, desloratadine and 3-hydroxydesloratadine.The present application uses lopatadine-d4, desloratadine-d5, 3-hydroxydesloratadine-d4 as deuterium internal standard, using Agilent, ZORBAX Eclipse XDB-Phenyl is carried out gradient elution, deuterium internal standard and the measured substance has the same retention time, chemical property and matrix effect, the reproducibility, accuracy of determining the concentration of lopatadine, desloratadine and 3-hydroxydesloratadine in plasma are good.The method of the present application can be used to evaluate the bioequivalence of lopatadine.

The invention discloses a method for detecting the concentration of Hetrombopag in human plasma through high performance liquid chromatography-tandem mass spectrometry. The method comprises the following steps: adding an internal standard Eltrombopag-13C4 and a precipitator into a plasma sample, uniformly mixing, centrifuging, and taking a supernatant; performing high performance liquid chromatography-tandem mass spectrometry detection on the supernate, and calculating by combining a standard curvilinear equation to obtain the concentration of the Hytrombopag in the human plasma. Through methodology verification of specificity, accuracy, precision, matrix effect, dilution reliability, residue, stability and the like, the detection method can be applied to detection analysis and pharmacokinetic research of a clinical patient hitrombopag plasma sample, so that the use dosage of the medicine is reasonably adjusted, and a safer and more effective individualized medication scheme is provided for the patient.

The invention discloses a high-sensitivity Tau-441 electrochemical immunosensor based on a nano material synergistic amplification effect as well as a preparation method and application of the high-sensitivity Tau-441 electrochemical immunosensor. According to the sensor, a silk-screen printing electrode (SPE) is used as a substrate, a PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode is used as a sensing platform, and electron transfer is promoted by using the large specific surface area and excellent conductivity of the PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode. Meanwhile, gold-modified magnetic nanoparticles (Fe3O4-coated AuNPs) are prepared as a signal probe, and the magnetic separation and enrichment function of Fe3O4 and the biocompatibility and catalytic activity of the gold nanoparticles are combined. The sandwich immune complex is constructed by adopting a homogeneous reaction mode, so that the mass transfer resistance is effectively reduced, and the detection time is shortened. The sensor has an extremely low detection limit (19.68 fgmL <-1 >) and a wide linear range on an Alzheimer's disease marker Tau-441, is high in specificity and good in stability, and is suitable for early-stage rapid screening of human plasma samples.

Inventors describe herein the functional and structural characteristics of the MGL from the anaerobic alkaliphilic thermophile Thermobrachium celere (TcMGL), which was compared to that from Pseudomonas putida (PpMGL). Catalysis was limited to L-Met, L-homocysteine, and L-cysteine, with the highest catalytic efficiency (keat / KM) towards L-Met. The half-life of active TcMGL in human plasma at 37°C was 9.2 hour. Half-life increased from 11.3 hour to 66.7 hour with increasing PLP concentration from 2 to 200 µM, in much greater magnitude than in PpMGL case. TcMGL crystal structure resolution revealed that the enzyme is a tetramer of two catalytic dimers containing a mobile region with open and closed conformations resulting in differences for access to the active site. TcMGL possesses favourable characteristics which makes it a suitable candidate for treatment of cancer. The present invention relates to a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO: 1 or a function-conservative variant thereof.

The invention discloses a method for extracting protein from human plasma for protein analysis, and relates to the technical field of plasma treatment, the key points of the technical scheme are as follows: the method effectively removes high-abundance protein, lipid and other interfering substances in the plasma through two steps of protein precipitation with acetone, degreasing and high-abundance protein removal; the method is suitable for subsequent protein identification and quantitative analysis. A stable and reliable method is provided for pretreatment of the plasma sample, a technical basis is provided for further use of protein in plasma for various medical analyses, and further development of the technology in the plasma detection field is facilitated.

The present application relates to a kind of PLOD2 gene and / or protein as biomarker in the application of preparation auxiliary MASH detection kit.It is also provided that the reagent for detecting the expression amount of PLOD2 in sample is applied to the preparation of auxiliary detection MASH detection kit.The present application finds that the content of PLOD2 in the plasma exosome of patient with metabolic dysfunction-related steatohepatitis is up-regulated, suggesting that the plasma or serum exosome rich in PLOD2 can be used as a new non-invasive biomarker, which can be used for early diagnosis and early treatment of auxiliary MASH patient, and for the progress research and drug research of MASH.

The invention relates to the technical field of analysis and detection, in particular to a kit and a method for extracting catecholamine and metabolites thereof based on a paramagnetic particle method and a method for detecting catecholamine and metabolites thereof by LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry). The kit comprises magnetic beads, an activating solution, an eluent, a washing solution, a leacheate I, a leacheate II and a derivatization reagent, the catecholamine and the metabolite thereof comprise one or more of dopamine hydrochloride, epinephrine, noradrenaline hydrochloride, methoxynoradrenaline hydrochloride, methoxyepinephrine hydrochloride and 3-methoxytyramine hydrochloride. The in-vivo concentration of catecholamine and metabolites thereof in human plasma and urine is detected in a high-flux manner by adopting a magnetic bead and derivation method, and the kit has the characteristics of high sensitivity, good repeatability, high accuracy, good specificity and the like.

The application relates to a method for quantitatively detecting the concentration of thioctic acid in human plasma by liquid chromatography-tandem mass spectrometry, and belongs to the technical field of biological sample detection. The method comprises the following steps: EDTA-K2 anticoagulant human plasma is taken, thioctic acid-d5 internal standard working solution is added, the mixture is uniformly mixed, acetonitrile is added to precipitate proteins, the supernatant is taken by centrifugation and is diluted; a C18 chromatographic column is used, 0.1% acetic acid aqueous solution and acetonitrile are used as mobile phases for gradient elution; mass spectrometric detection adopts an electrospray ion source negative ion mode and a multiple reaction monitoring mode, the ion pair of thioctic acid is m / z 205.100->171.100, and the ion pair of the internal standard is m / z 210.050->174.100; the peak area ratio is used as a quantitative index, 1 / C 2 weighted linear regression is used to establish a standard curve. The method has the advantages of simple pretreatment, high sensitivity, rapid analysis, strong anti-matrix interference ability, and is suitable for the detection of conventional and hemolytic and hyperlipidemic plasma samples, and can be used for pharmacokinetic research and clinical detection of thioctic acid.

The present application belongs to the technical field of biological detection, and particularly relates to a non-invasive selenium level prediction method based on saliva selenoprotein P detection and application. The present application immunizes mice with heterologously expressed antigen SELENOP (40-194 aa) to generate antibodies, and monoclonal antibodies capable of efficiently recognizing SELENOP are screened and obtained; an ELISA detection method is established using the obtained monoclonal antibodies. The selenium content in human plasma and saliva is detected and analyzed using the detection method and an ICP-MS selenium content detection method, and it is found that there is a significant positive correlation between the three, and a correlation curve between saliva selenoprotein P and human plasma selenium content is established, thereby achieving the purpose of evaluating human selenium level through non-invasive saliva selenoprotein P detection. The technical scheme provided by the present application can be used for large-scale screening and routine health monitoring.

The invention discloses a preparation method of a neonatal ABO hemolytic disease detection simulation specimen in blood transfusion medicine teaching, which comprises the following steps: a, collecting blood plasma or serum of healthy people, and absorbing IgM anti-A, anti-B and anti-AB; b, separating the absorbed plasma or serum, and taking the upper-layer plasma or serum for later use; c, sensitizing corresponding blood type red blood cells, namely absorbing IgG anti-A or anti-B by the A type or B type red blood cells, and preparing a simulation specimen; and d, preserving the specimen. The method disclosed by the invention is simple to operate, and the prepared specimen is a simulated specimen and is used for detecting the neonatal ABO hemolytic disease as an experimental content in blood transfusion medical experiment teaching. The use of the simulation specimen is convenient for students to learn and understand the experiment operation technology in blood transfusion medical experiment teaching, solves the problem that the newborn ABO hemolytic disease detection specimen is not easy to obtain, and meets the requirements of blood transfusion medical experiment teaching.

A process is provided for inhibiting or preventing symptoms of necrotizing enterocolitis in a subject that includes the oral administration to the subject of a human polyclonal secretory IgA formed by the conjugation of human recombinant secretory component and pooled human plasma derived dimeric and polymeric. When administered in a therapeutic quantity, symptoms of necrotizing enterocolitis in the subject are inhibited or precluded.

Disclosed are compounds of formula Ias described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

The application discloses a methylation marker combination for detecting early esophageal cancer and application thereof. The marker combination comprises 178 methylation sites of 12 specific DNA regions and a specific internal marker region, and the methylation levels of the regions in plasma of patients with early esophageal cancer and healthy people are significantly different. The application also provides a primer combination and a kit for detecting the marker combination, and supports high-throughput deep sequencing. A detection system is used to extract plasma free DNA, perform bisulfite conversion and amplification, calculate a prediction value by using a logistic regression model, multiply the average methylation rate of each region by a corresponding weight coefficient, and compare the result with a threshold value to make a positive judgment. The application greatly improves the detection sensitivity of non-invasive screening for early esophageal cancer under the premise of ensuring high specificity, and has a wide clinical application prospect.

This invention relates to a photoanode material based on a porphyrin covalent organic framework@polyindolepentaformaldehyde, its preparation method, and its application, belonging to the field of photoelectrochemical biosensor technology. This invention uses Dha and Tph to synthesize D-T-COF via a solvothermal method, and modifies it onto the surface of an FTO conductive substrate; further, P5FIn is deposited via electropolymerization to form a uniform and widely distributed layer on the D-T-COF surface. p‑n Heterogeneous junction structure. Based on D-T-COF@P5FIn composite material and p-tau217 capture antibody, an opto-chemical immunosensor array capable of accurately identifying trace amounts of p-tau217 in human plasma was constructed. It has achieved significant breakthroughs in sensitivity, specificity and practicality, and is particularly suitable for the reliable detection of extremely low concentrations of biomarkers in complex biological matrices, showing broad prospects for clinical translational applications.

The invention relates to the technical field of chromatographic detection, in particular to a method for measuring the concentration of cefditoren in K2EDTA human plasma through LC-MS / MS. Comprising the following steps: preparing a standard curve sample containing cefditorem-d3, a quality control sample, a test sample containing cefditoren, a blank sample, a zero-concentration sample and a quantitative upper limit sample without adding an internal standard; and detecting the standard curve sample containing cefditorem-d3, a quality control sample, a test sample containing cefditoren, a blank sample, a zero-concentration sample and a quantitative upper limit sample without internal standard by using a liquid chromatography-tandem mass spectrometry method. By optimizing chromatographic conditions and mass spectrum parameters, the invention provides an efficient and accurate method for detecting the concentration of the cefditoren drug, the concentration of the cefditoren in the blood plasma can be accurately determined, and the accuracy and reliability of data are ensured.

The application discloses a new type of high-performance liquid chromatography-tandem mass spectrometry analysis method for detecting lanreotide in human plasma, enriches the lanreotide by using a liquid-liquid extraction method, and the quantitative lower limit is 0.05 ng / mL. By liquid-liquid extraction treatment, the interfering substances in human plasma can be removed, and the matrix effect is improved. The solvent composition and pH value of the liquid-liquid extraction are optimized, and the purpose of effective extraction is achieved. The lanreotide standard is used to prepare a standard curve, and the result is corrected by using the lanreotide isotope internal standard, and the detection result has good accuracy. Without additional preparation of antibody reagents, the operation is simple. The method has high sensitivity, specificity and reproducibility, and has many advantages compared with the traditional radioimmunoassay.

The invention relates to a method for determining kininogenase and a used kit. On one hand, the invention relates to a kit for determining the content of kininogenase in human plasma, the kit comprises a test solution for testing, an antigen standard substance, a capture antibody, an enzyme-labeled antibody and a test method description file which are separately packaged by containers, and the test solution comprises PBS, PBST, a washing solution, a confining solution, a sample diluent, a stop solution, a coating buffer solution, a color developing solution A and a color developing solution B. The invention also relates to a method for determining the content of kininogenase in human plasma by using the kit. According to the kit and the method provided by the invention, the amount of endogenous kininogenase or exogenous kininogenase in a human body can be accurately and effectively measured, and a beneficial tool is provided for diagnosis and treatment of clinical diseases.

The invention relates to the technical field of biomedical analysis, in particular to a clinical steroid hormone determination method which comprises the following steps: repeatedly treating human plasma by adopting a solid-phase extraction method, using octadecylsilane bonded silica gel filler, extracting to remove endogenous steroid hormone, and obtaining a human plasma blank matrix; the method comprises the following steps: respectively preparing a steroid hormone stock solution and a loratadine internal standard solution, taking the human plasma blank matrix treated in the step 1, adding the loratadine internal standard solution, treating with a 2% formic acid solution, extracting by using an HLB solid-phase extraction column, centrifugally concentrating an eluent, redissolving for LC-MS / MS analysis, carrying out sample analysis by adopting an LC-MS / MS method, and determining the content of the loratadine in the human plasma blank matrix. And detecting in an ESI positive ionization mode. Therefore, multiple steroid hormones can be detected at the same time, the coverage concentration range is wide, endogenous interference can be effectively removed, the detection accuracy is improved, the sensitivity is high, the repeatability is good, and the method is suitable for high-throughput analysis of clinical samples.

The present invention relates to medical uses comprising the administration of anti-human CCR8 antibodies in specifically defined dosage regimens in monotherapy or combination therapy with an anti-PD-(L)1 antibody. The dosing schemes were developed for anti-human / cynomolgus CCR8 antibody TPP-23411, but they can also be used for other antibodies having similar properties as TPP-23411. The medical uses or dosage regimens may comprise a stratification step to select patients with an increased probability of treatment success. Suggested biomarkers are a) Tumor Proportion Score or Combined Positive Score as a measure for PD-(L)1 expression, b) analysing in a blood, plasma or serum sample inflammatory cytokines and c) previous treatment of the cancer for at least 6 months with an anti-PD-(L)1 antibody. Furthermore, provided are anti-human CCR8 antibody-based medical uses and treatment methods comprising the administration of a Zr-89-labeled anti-CD8 minibody to determine the abundance and / or distribution of CD8 cells by means of a PET scan for stratification or for monitoring treatment success or disease progression. Also provided is a method to reliably determine an anti-anti-CCR8 antibody in cynomolgus or human plasma. Finally, an anti-murine CCR8 surrogate antibody is disclosed that mimics the unusual half-life of TPP-23411.